Distinct CSF biomarker-associated DNA methylation in Alzheimer's disease and cognitively normal subjects.

ABSTRACT: Background Growing evidence has demonstrated that DNA methylation (DNAm) plays an important role in Alzheimer's disease (AD) and that DNAm differences can be detected in the blood of AD subjects. Most studies have correlated blood DNAm with the clinical diagnosis of AD in living individuals. However, as the pathophysiological process of AD can begin many years before the onset of clinical symptoms, there is often disagreement between neuropathology in the brain and clinical phenotypes. Therefore, blood DNAm associated with AD neuropathology, rather than with clinical data, would provide more relevant information on AD pathogenesis. Methods We performed a comprehensive analysis to identify blood DNAm associated with cerebrospinal fluid (CSF) pathological biomarkers for AD. Our study include

SUBMITTER: Zhang W 

PROVIDER: S-EPMC9980279 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature